• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The Effect of Dexamethasone Treatment on COVID-19 Prognosis in Cancer Patients
CONCLUSION: Our data showed that dexamethasone therapy protocol affected COVID-19 prognoses in cancer patients, and it is preferable to not discontinue therapy after infection. A rigorous prospective comparison between early and late dexamethasone dosing is needed to determine the best protocol for treatment.PMID:36366306 | DOI:10.3390/vaccines10111798
Source: Cancer Control - November 11, 2022 Category: Cancer & Oncology Authors: Lina Souan Zienab Al-Khairy Maysaa' Adnan Al-Binni Abdelkader Battah Maher A Sughayer Source Type: research

Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
Leukemia. 2022 Apr 29. doi: 10.1038/s41375-022-01578-1. Online ahead of print.ABSTRACTSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS-CoV-2 infection is characterised by an initial viral phase followed in some patients by a severe inflammatory phase. Importantly, immunocompromised patients may have a prolonged viral phase, shedding infectious viral particles for months, and absent or dysfunctional inflammatory phase. Among haematological patients, COVID-19 has been associated with high mortality rate i...
Source: Cancer Control - April 29, 2022 Category: Cancer & Oncology Authors: Simone Cesaro Per Ljungman Malgorzata Mikulska Hans H Hirsch Marie von Lilienfeld-Toal Catherine Cordonnier Sylvain Meylan Varun Mehra Jan Styczynski Francesco Marchesi Caroline Besson Fausto Baldanti Raul Cordoba Masculano Gernot Beutel Herman Einsele El Source Type: research

Improved T cell immunity following neoadjuvant chemotherapy in ovarian cancer
CONCLUSIONS: NACT may alleviate tumor-associated immunosuppression by reducing tumor burden and may enhance antigen processing and presentation. These findings have implications for the successful combinatorial applications of immune checkpoint blockade and therapeutic vaccine approaches in EOC.PMID:35443043 | DOI:10.1158/1078-0432.CCR-21-2834
Source: Clinical Cancer Research - April 20, 2022 Category: Cancer & Oncology Authors: Min Liu Nabihah Tayob Livius Penter MacLean Sellars Anna Tarren Vipheaviny Chea Isabel Carulli Teddy Huang Shuqiang Li Su-Chun Cheng Phuong Le Laura Frackiewicz Julia Fasse Courtney Qi Joyce F Liu Elizabeth H Stover Jennifer Curtis Kenneth J Livak Donna N Source Type: research

Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study
In this study, we used comprehensive hospitalisation data to estimate vaccine effectiveness over time.METHODS: In this case-control study, we used data from a large US health-care system to estimate vaccine effectiveness against severe SARS-CoV-2 infection and examined variation based on time since vaccination, vaccine type, and patients' demographic and clinical characteristics. We compared trends in attenuation of protection across vaccines and used a multivariable model to identify key factors associated with risk for severe breakthrough infection. Patients were considered to have severe COVID-19 if they were admitted t...
Source: Respiratory Care - March 1, 2022 Category: Respiratory Medicine Authors: Bill J Wright Samuel Tideman George A Diaz Thomas French Guilford T Parsons Ari Robicsek Source Type: research

A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma
CONCLUSIONS: In this trial, treatment of newly diagnosed and recurrent glioblastoma with autologous dendritic cell vaccine pulsed with lysate derived from an allogeneic stem-like cell line was safe and well-tolerated. Clinical outcomes add to the body of evidence suggesting that immunotherapy plays a role in the treatment of glioblastoma.PMID:34862245 | DOI:10.1158/1078-0432.CCR-21-2867
Source: Clinical Cancer Research - December 4, 2021 Category: Cancer & Oncology Authors: Jethro L Hu Oluwaseun A Omofoye Jeremy D Rudnick Sungjin Kim Mourad Tighiouart Surasak Phuphanich Hongqiang Wang Mia Mazer Toni Ganaway Ray M Chu Chirag G Patil Keith L Black Stephen L Shiao Rong-Fu Wang John S Yu Source Type: research

Fight Aging! Newsletter, September 28th 2020
In conclusion, it remains unclear if brain-specific regional and temporal changes occur in the expression of the different APP variants during AD progression. Since APP is also found in blood cells, assessing the changes in APP mRNA expression in peripheral blood cells from AD patients has been considering an alternative. However, again the quantification of APP mRNA in peripheral blood cells has generated controversial results. Brain APP protein has been analyzed in only a few studies, probably as it is difficult to interpret the complex pattern of APP variants and fragments. We previously characterized the soluabl...
Source: Fight Aging! - September 27, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Cancers, Vol. 10, Pages 492: Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?
nin To date, no targeted drugs, antibodies or combinations of chemotherapeutics have been demonstrated to be more efficient than temozolomide, or to increase efficacy of standard therapy (surgery, radiotherapy, temozolomide, steroid dexamethasone). According to recent phase III trials, standard therapy may ensure a median overall survival of up to 18–20 months for adult patients with newly diagnosed glioblastoma. These data explain a failure of positive non-controlled phase II trials to predict positive phase III trials and should result in revision of the landmark Stupp trial as a historical control for ...
Source: Cancers - December 5, 2018 Category: Cancer & Oncology Authors: Aleksei A. Stepanenko Vladimir P. Chekhonin Tags: Review Source Type: research